Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat PK in hepatic impairment
NCT03799848Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Jun 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Akebia Therapeutics. Primary endpoints: Area under the concentration-time curve from dosing to last measurable concentration at Day 4, Area under the concentration-time curve from dosing to infinity at Day 4 and 1 more. Started Jun 2018; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03799848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799848.